TNXP: Tonix Pharmaceuticals Holding Corp. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 36.31
Enterprise Value ($M) 16.07
Book Value ($M) 74.21
Book Value / Share 0.40
Price / Book 0.49
NCAV ($M) 29.77
NCAV / Share 0.16
Price / NCAV 1.22

Profitability (mra)
Return on Invested Capital (ROIC) -1.63
Return on Assets (ROA) -0.88
Return on Equity (ROE) -1.28

Liquidity (mrq)
Quick Ratio 2.81
Current Ratio 3.33

Balance Sheet (mrq) ($M)
Current Assets 50.54
Assets 94.99
Liabilities 20.78
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
11-14 13G/A Armistice Capital, Llc 0.83 -60.21
10-16 13G/A Empery Asset Management, LP 1.34 -24.80
06-20 13G L1 Capital Global Opportunities Master Fund, Ltd. 9.99
02-14 13G Alyeska Investment Group, L.P. 9.99
02-14 13G/A Tang Capital Partners Lp 0.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 50,543,822 115,540,920 43.75
2025-02-03 94,056,275 245,968,945 38.24
2025-01-31 26,727,872 64,033,355 41.74
2025-01-30 31,169,979 74,137,971 42.04

(click for more detail)

Similar Companies
TIL – Instil Bio, Inc. TLSA – Tiziana Life Sciences Ltd
TNFA – TNF Pharmaceuticals, Inc. TPST – Tempest Therapeutics, Inc.
TRAW – Traws Pharma, Inc.


Financial data and stock pages provided by
Fintel.io